Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.4314
-0.0535 (-11.03%)
At close: Oct 15, 2026, 4:00 PM EDT
0.5157
+0.0843 (19.54%)
After-hours: Oct 15, 2026, 7:59 PM EDT
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 11 employees as of December 31, 2025. The number of employees decreased by 2 or -15.38% compared to the previous year. That makes Biodexa Pharmaceuticals the 39,878th largest employer in the world and 5,977th in the United States.
Employees
11
Change (1Y)
-2
Growth (1Y)
-15.38%
Revenue / Employee
n/a
Profits / Employee
-$533,127
Market Cap
443.94K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11 | -2 | -15.38% |
| Dec 31, 2024 | 13 | -8 | -38.10% |
| Dec 31, 2023 | 21 | -6 | -22.22% |
| Dec 31, 2022 | 27 | 7 | 35.00% |
| Dec 31, 2021 | 20 | 2 | 11.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Scinai Immunotherapeutics | 45 |
| Virax Biolabs Group | 26 |
| Curis | 24 |
| Silexion Therapeutics | 14 |
| Decoy Therapeutics | 11 |
| Artelo Biosciences | 7 |
| CDT Equity | 4 |
BDRX News
- 2 days ago - Biodexa Pharmaceuticals enrolls 100 patients in eRapa trial - TheFly
- 2 days ago - Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP - GlobeNewsWire
- 21 days ago - Biodexa Pharmaceuticals files to sell 220.42M ordinary shares for holders - TheFly
- 21 days ago - Biodexa Pharmaceuticals Registration statement: Registration filing - Filings
- 22 days ago - The Longview: Fireside Chat with Biodexa CEO Stephen Stamp - Accesswire
- 4 weeks ago - Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds - GlobeNewsWire
- 4 weeks ago - Biodexa Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Interim results for the six months ended June 30, 2026 - GlobeNewsWire